Catalyst Event
Astrazeneca PLC (AZN) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/13/2026, 12:00:00 AM
The FDA approved the first generic versions of AstraZeneca's blockbuster Type 2 diabetes drug, Farxiga, on April 13, 2026. This will introduce significant competition and likely lead to sales erosion.
Korean Translation
2026년 4월 13일, FDA가 아스트라제네카의 블록버스터 2형 당뇨병 치료제 '포시가'의 첫 제네릭 버전을 승인함. 이는 상당한 경쟁을 유발하고 매출 감소로 이어질 가능성이 높음.
Related Recent Events
Novo Nordisk A/S (NVO) · Earnings Release
Novo Nordisk is scheduled to release its Q1 2026 earnings report before the market opens on May 6, 2026, with high importance estimated due to potential 10% price impact, expected.
5/6/2026, 12:00:00 AM
Life Time Group Holdings Inc (LTH) · Earnings Release
Life Time Group Holdings is scheduled to report its Q1 2026 financial results. A moderate market reaction is estimated for this standard earnings release scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026, followed by a conference call. High impact is estimated due to significant market focus on GLP-1 sales growth scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is scheduled to release its Q1 2026 earnings on April 30, 2026; impact is estimated as neutral pending the actual report, scheduled.
4/30/2026, 12:00:00 AM
Amgen Inc (AMGN) · Earnings Release
Amgen is expected to report its Q1 2026 financial results after the market closes on April 30, 2026, scheduled. Analysts estimate a Low impact (~1-2%) as a standard scheduled reporting event, scheduled.
4/30/2026, 12:00:00 AM
Astrazeneca PLC (AZN) · Earnings Release
AstraZeneca's Q1 2026 results announcement is scheduled for April 29, 2026 scheduled
4/29/2026, 12:00:00 AM